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There are no preclinical data on the concomitant use of DLI and Bex. In addition, a sequential approach employing singleagent treatment in patients with CTCL has been as effective as drug combinations with less toxicity [10] .
This trial employed sequential treatment starting with DLI followed by Bex in patients with refractory and/or late-stage CTCL with two objectives. The first was to determine the progression-free survival of DLI followed sequentially by Bex. The second was to determine the ORR of the sequential combination using strict criteria.
methods eligibility
Patients enrolled had TNM stages IB and IIA poorly responsive to skindirected therapies or IIB-IV CTCL. Staging was carried out according to standard criteria used in 2005 when the trial was initiated [11] . Karnofsky performance status (KPS) was ≥60. with adequate organ function. Prior treatment with doxorubicin or Bex was permitted provided the patients had not progressed on these agents. The use of topical corticosteroids with the exception of Class 1 was also permitted for patients with intense pruritus. This was a multi-institutional clinical trial, approved by institutional review/ privacy boards, and all patients gave written informed consent. The treatment protocol was registered with ClinicalTrials.gov (NCT00255801).
trial design
This was an open-label phase II trial with a planned enrollment of 37 patients. At baseline, patients underwent history and physical examination with KPS and skin score determination, routine laboratory studies and baseline Sézary counts and/or flow cytometry as appropriate. Computed tomography (CT) of the chest, abdomen and pelvis was carried out for TNM stage IV disease.
Eligible patients received DLI 20 mg/m 2 i.v. every 2 weeks for 16 weeks (8 treatments). Responses were assessed, and all patients who did not progress subsequently received Bex 300 mg/m 2 orally daily for 16 weeks. Patients received prophylactic blood lipid-lowering agents, and thyroid replacement therapy for transient hypothyroidism was administered as required [9] . Prophylactic antibiotics and in-dwelling intravenous catheters were not used. Follow-up evaluations were carried out at each DLI treatment visit every 2 weeks during the first 16 weeks. During the second 16-week phase of treatment with Bex, patients were seen on week 18, 20, 24, 28 and 32. Toxicity was assessed using the NCI Common Toxicity Criteria for Adverse Events v3.0. Tumor assessments were carried out within 2 weeks following the first 16-week period of treatment with DLI and again following the second 16-week treatment with Bex. These evaluations included CBC (with Sézary counts and/or flow cytometry for patients with Sézary syndrome), toxicity, KPS, CT of chest, abdomen and pelvis (for patients with TNM stage IV disease), pruritus score and dermatological assessment of response. The pruritus scale was a self-reported 1-10-point visual analog scale where 0 indicates no pruritus and 10 indicates the worst imaginable pruritus [12] .
Primary skin tumor assessments were made by the modified SeverityWeighted Assessment Tool (mSWAT) [12, 13] ; the Composite Assessment of Index Lesion Severity (CA) [9, 14] was used a secondary scale.
Progression was defined as ≥25% increase in mSWAT skin score and ≥50% increase in the sum of the products of the greatest diameters of involved lymph nodes over baseline for patients with involved lymph nodes with stage IV disease.
statistical analysis
This was a phase II, multicenter, open-label single-arm trial. The statistical end point was PFS at 12 months. In the literature as of 2005 when the trial was initiated, the median PFS was 12 months for treatment with DLI as a single agent [3] . The goal was to achieve a 12-month PFS rate of 70%. Thirty-seven patients were required with a conventional type I error 0.05 and power 0.8. A second end point was ORR (CR + PR) as determined by mSWAT, and imaging and blood studies for stage IV disease. A second assessment of skin response was by CA.
results
Between 29 November 2005 and 11 January 2011, 37 patients (20 males and 17 females) were enrolled. The median age was 56 years (range 27-81 years) ( Table 1 ). The median time from initial diagnosis to study enrollment was 46 months (range 1-306 months). All patients had prior skin-directed therapy (topical with or without radiation therapy). Fourteen patients refractory to such treatment had no prior systemic therapy. Twenty-three patients received prior systemic therapy (median 2, range 1-11). Three patients were stage IB, two stage IIA, 10 (15-43 months) . Thirty-four of 37 patients were assessable for response. Of the three not assessable patients, two withdrew consent and one died 5 days after starting treatment. During DLI treatment, delays were necessary in eight patients due to palmar plantar erythrodysesthesia (PPE) (three), infection (three), neutropenia (one) and stomatitis (one). In addition, dose reductions were necessary in two of these patients, one for PPE and one for stomatitis. During Bex treatment, there were delays in five patients due to hypertriglyceridemia (two), hypertriglyceridemia and neutropenia (two) and PPE (one). In addition, a dose reduction was made in one of these patients for hypertriglyceridemia.
The ORR was 41% with 12 PRs (stages IV 7; IIB 3; IIA 1; IB 1) and two clinical complete response (CCR; both stage IV) (Table 2) . Six patients had stable disease (SD). Fourteen patients progressed before completing eight cycles of DLI (median 5 cycles; range 1-8). One of the patients who achieved a PR on this trial had previously received DLI in combination with gemcitabine and bortezomib, and was the only patient who was previously treated with an anthracycline. Twenty patients with a CCR, PR or SD following 16 weeks of DLI were eligible to continue protocol treatment with 16 weeks of Bex. Five eligible patients did not receive Bex for the following reasons: one patient with SD withdrew from the trial for unspecified reasons, two elected to continue on DLI, one withdrew after finding a match for a bone marrow transplant and one was discontinued for insurance coverage reasons. Fifteen patients were treated with Bex. Six patients progressed during treatment. Nine patients completed 16 weeks of Bex with continuation of responses achieved with DLI: 1 CCR, 6 PR and 2 SD. All maximal response categories were seen after the first 16 weeks of treatment with DLI. No patients who failed to respond to DLI responded to Bex, and no patient who achieved PR on DLI achieved CR/ CCR on Bex. Ten of the 14 responders received prior systemic treatment; 4 of the 14 responders had Sézary syndrome. There was complete concordance of skin responses according to the primary mSWAT scale and secondary CA scale. The median PFS was 5 months. A patient's mSWAT scores in Figure 1 show a PR after the first 16 weeks of DLI. Although further improvement was seen with Bex, criteria were not met for CR/CCR.
There were 22 deaths following discontinuation of protocol treatment, 21 of disease progression and one of congestive heart failure 3 months after completing treatment in a patient with a pretreatment left ventricular ejection fraction of 60%, no prior anthracycline treatment and a history of type 2 diabetes, hypertension and chronic obstructive pulmonary disease. The median overall survival (OS) was 18 months.
Improvements in pruritus scores were seen in patients with stable disease as well as those achieving a major tumor response (supplementary Table S1 , available at Annals of Oncology online). There were 27 grade 3 and 5 grade 4 toxicities reported among 16 patients (47%). There were two grade 3 and four grade 2 instances of PPE. During the Bex phase of treatment, hypertriglyceridemia despite concurrent use of lipid-lowering agents was reported in 10 patients (27%): 8 grade 1/2, 1 grade 3 and 1 grade 4 (supplementary Table S2 , available at Annals of Oncology online).
discussion
A phase I trial of Bex was conducted at Memorial SloanKettering Cancer Center in which responses were seen in CTCL, even at low doses [15] . This provided the basis for the pivotal multi-institutional phase II trials which led to FDA approval in CTCL [8, 9] . As a follow-up to those single-agent trials, the combination of Bex with interferon alfa was found to produce a similar response rate to that for Bex alone [14] . Thus, a sequential approach of DLI followed by Bex rather than a combination was selected for the current trial in an attempt to increase the response rate and durability. The dose of DLI was the same as that for Kaposi's sarcoma, although administration every 2 rather than 3 weeks was found by us and others to be well tolerated [16] . A different dose and schedule have been used for small trials using nonpegylated liposomal doxorubicin [17] .
The trial failed to meet its primary target of a 12-month PFS of 70% indicating that the sequential approach did not seem to improve results observed with DLI alone. Nevertheless, the 41% ORR in advanced CTCL patients with DLI compares favorably with reported response rates for chemotherapeutic and biological agents reported in recent trials using similar strict response criteria [9, 12, 18, 19] .
Although no patient achieved new major response (SD to PR/ CR/CCR) or improved from PR to CR/CCR with Bex following DLI, some patients continued to have skin improvement with Bex ( Figure 1 ) which demonstrates the limitation of mSWAT in correlating response with clinical benefit as demonstrated in the photograph.
It is possible that responses would have been improved and prolonged by continuing DLI in responding patients rather than changing treatment to Bex after the initial 16 weeks. Continuing systemic treatment until there is no further clinical benefit has been the standard approach to treating CTCL [10] . A similar strategy of continuing DLI with periodic cardiac monitoring while patients derive clinical benefit has also been successful in treatment of HIV-related Kaposi's sarcoma [20, 21] .
Improvements in patient-reported pruritus scale results were noted in patients with CCR, PR and SD. This suggests clinical benefit to treatment with DLI even in patients who fail to meet criteria for objective response. Similar observations were made for treatment with vorinostat [12] . Prophylactic antiemetic drugs were not used with DLI because of the low risk of emesis. This could have confounded this result because aprepitant has been found to reduce pruritus in Sézary syndrome [22] .
Based on FDA recommendations for objective reproducible response criteria for CTCL, more precise and stringent reporting of pivotal trial results have appeared in the recent literature [8, 9, 12, [23] [24] [25] . These criteria, including, most importantly the mSWAT, have been incorporated into proposals of the International Society for Cutaneous Lymphomas published in 2011 [26] . This may have contributed to the discrepancy in the response results reported here for CTCL and those previously reported. It is difficult to compare our results with DLI to those with other chemotherapeutic agents because earlier studies employed less stringent response criteria [3] [4] [5] [6] .
The results of a multi-institutional phase II trial of DLI in stage IIB, IVA and IVB mycosis fungoides conducted by the European Organisation for Research and Treatment of Cancer (EORTC) have been recently reported in 49 patients at the same dose and schedule as our trial with an identical response rate [16] .
In conclusion, even with stringent response criteria, the 41% ORR is comparable with that reported for the most active single systemic agents for CTCL in the literature. The toxicity profile is favorable which makes it an attractive treatment choice, especially in stage IV. Strategies to combine active agents in CTCL, either concurrently or sequentially, remain a challenge.
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